









Tissue based biomarkers in non-
clear cell RCC: Correlative analysis 
from the ASPEN clinical trial
The Pathway of Belzutifan, from 
clinical trials to clinical practice
Q&A on Advances in 
Treatment Landscape of mRCC:





J O U R N A LOfficial Journal of The Kidney Cancer Association
The Current and Evolving 
Therapeutic Paradigm in mRCC
64       K i d n e y  C a n C e r  J o u r n a l  | 19 (3) |Oct 2021 www.kidney-cancer-journal.com  
Tissue based biomarkers in non-clear cell RCC: 
Correlative analysis from the ASPEN clinical trial 
Susan Halabi PhD1, Qian Yang1 Andrea Carmack MB1, Shiqi Zhang1, Wen-Chi Foo1, Tim Eisen MD2, Walter M. Stadler MD3, Robert J. Jones 
MD4, Jorge A. Garcia MD5, Ulka N. Vaishampayan MD6, Joel Picus MD7, Robert E. Hawkins MD8, John D. Hainsworth MD9, Christian K. 
Kollmannsberger MD10,  Theodore F. Logan MD11, Igor Puzanov MD12, Lisa M. Pickering MD13, Christopher W. Ryan MD14, Andrew Protheroe 
MD15, Daniel J. George MD16,  Andrew J. Armstrong MD16*
1. Department of  Biostatistics and Bioinformatics, Duke University, Durham NC;
2. University of  Cambridge, Cambridge, United Kingdom; 
3. University of  Chicago, Chicago, IL USA;
4. University of  Glasgow, The Beatson West of  Scotland Cancer Centre, Glasgow, United Kingdom; 
5. Cleveland Clinic, Cleveland, OH USA;
6. University of  Mic higan, Ann Arbor/Karmanos Cancer Institute, Wayne State University, Detroit, MI USA; 
7. Washington University in St. Louis, St. Louis, MO USA;
8. Christie Cancer Research Centre, Manchester, United Kingdom; 
9. Sarah Cannon Research Institute, Nashville, TN USA;
10. BCCA Vancouver Cancer Centre, Vancouver, BC Canada; 
11. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA;
12. Roswell Park Comprehensive Cancer Center, Buffalo, New York (Previously at Vanderbilt University Medical Center, Nashville, TN USA); 
13. Royal Marsden Hospital, London, United Kingdom;
14. Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR USA; 
15. University of  Oxford Medical Oncology Department, Oxford, United Kingdom; 
16. Duke University and the Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC; 
INTRODUCTION
Non-clear cell renal cell carcinoma 
(NC-RCC) comprises a genetically and 
histologically diverse set of cancers, 
including type 1 and 2 papillary renal 
cell carcinoma (RCC), chromophobe 
RCC, translocation carcinoma, as 
well as many other rare subtypes, 
some of which remain histologically 
unclassified1,2.  NC-RCC accounts for 
about 25% of all cases of RCC.  However, 
in the metastatic setting, the subtypes of 
NC-RCC that are most commonly found 
are type 2 papillary and unclassified 
NC-RCC given their more aggressive 
disease course1.  
We and others have recently 
reported on randomized prospective 
clinical trials comparing the vascular 
endothelial growth factor (VEGF) 
sunitinib with the mTOR inhibitor 
everolimus in patients with metastatic 
NC-RCC (ASPEN and ESPN)3,4. In 
these trials, sunitinib provided superior 
response rates and more durable 
control of disease; however, outcomes 
were heterogeneous based on histologic 
subtypes.  For example, patients with 
papillary RCC and unclassified RCC, 
as well as those patients with good/
intermediate risk disease had superior 
outcomes with sunitinib, while patients 
with chromophobe RCC and those 
with poor risk disease had superior 
outcomes with everolimus3.  We recently 
reported differential outcomes based 
on differential plasma angiokine and 
immunokine levels in this setting, which 
were quite heterogeneously expressed 
according to disease risk and histology 
and over time during treatment 
resistance5.  These data support the 
concept that these non-clear cell 
tumors should be regarded as distinct 
molecular and phenotypic entities 
with distinct treatment outcomes with 
molecularly targeted therapies, and has 
Biomarkers are needed in patients with non-clear cell renal cell carcinomas (NC-RCC), particularly papillary renal cell carcinoma, in order to inform on initial treatment selection and identify potentially novel targets for 
therapy. We enrolled 108 patients in ASPEN, an international randomized 
open-label phase 2 trial of patients with metastatic papillary, chromophobe, or 
unclassified NC-RCC treated with the mTOR inhibitor everolimus (n=57) or the 
vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib (n=51), 
stratified by MSKCC risk and histology.  The primary endpoint was overall 
survival (OS) and secondary efficacy endpoints for this exploratory biomarker 
analysis were radiographic progression-free survival (rPFS) defined by intention-
to-treat using the RECIST 1.1 criteria and radiographic response rates. Tissue 
biomarkers (n=78) of mTOR pathway activation (phospho-S6 and -Akt, c-kit) and 
VEGF pathway activation (HIF-1, c-MET) were prospectively explored in tumor 
tissue by immunohistochemistry prior to treatment and associated with clinical 
outcomes. We found that S6 activation was more common in poor-risk NC-RCC 
tumors and S6/Akt activation was associated with worse PFS and OS outcomes 
with both everolimus and sunitinib, while c-kit was commonly expressed in 
chromophobe tumors and associated with improved outcomes with both agents. 
C-MET was commonly expressed in papillary tumors and was associated with
lower rates of radiographic response but did not predict PFS for either agent.  In
multivariable analysis, both pAkt and c-kit were statistically significant prognostic
biomarkers of OS. No predictive biomarkers of treatment response were identified
for clinical outcomes. Most biomarker subgroups had improved outcomes with
sunitinib as compared to everolimus.
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been supported by retrospective studies 
suggesting a subset of patients with 
mTOR inhibitor sensitivity6.  
The identification of biomarkers 
predictive of treatment benefit is a major 
unmet need in the field of RCC therapy. 
In clear cell RCC, differential outcomes 
with immune checkpoint blockade have 
been observed in patients with tumors 
with sarcomatoid differentiation, those 
harboring particular immune subsets 
of T cell effector function, and perhaps 
certain complex genomic signatures 
7,8; however, these have not been 
established in non-clear cell RCC and 
are not commonly utilized to inform 
treatment selection.  While histology 
(clear cell disease) is predictive of the 
benefits of high dose IL-2, and serum 
LDH may be predictive of the benefits 
of mTOR inhibition in poor risk RCC, 
there are no other clear predictors 
of treatment response or survival to 
specific therapies.  An analysis of the 
RECORD-3 trial comparing sunitinib 
and everolimus identified several 
composite prognostic circulating 
biomarkers for progression-free 
survival with everolimus, but were 
unable to predict overall survival and 
the analyses were largely restricted to 
clear cell RCC9.  In addition, a subset 
of papillary RCC patients have disease 
that is driven by activation of the c-MET 
oncogene, and may benefit from c-MET 
inhibitors10.  Furthermore, recent 
data from the PAPMET randomized 
phase 2 trial suggests that dual VEGF/
c-MET targeting with cabozantinib 
may provide a greater probability of 
durable disease control as compared 
to sunitinib in patients with advanced 
papillary RCC11. 
Given the heterogeneity of genomic 
alterations and phenotype as well as 
clinical outcomes of patients with 
metastatic non-clear cell RCC, we 
sought to characterize markers of 
specific pathway activation linked to 
molecularly targeted therapies. To 
accomplish this, we utilized tissue 
based protein biomarkers of mTOR 
and VEGF/MET pathway activation 
in patients with metastatic non-clear 
cell RCC as part of the international, 
randomized, prospective clinical trial 
comparing sunitinib and everolimus 
(ASPEN).  We asked whether evidence 
of mTOR pathway activity or VEGF-
HIF-1α/MET expression differed by 
histologic subtype and MSKCC risk 
group12, 13, and  whether clinical efficacy 
outcomes differed by baseline tissue 
pathway biomarker expression at the 
protein level. Based these previous 
studies, familial syndromes of mTOR 
pathway activation in chromophobe 
RCC14 and c-met pathway activation 
in hereditary and sporadic papillary 
RCC15, and our own plasma biomarker 
analysis5, our specific a priori 
hypotheses were that pS6 and pAKT 
high level expression will be associated 
with a greater radiographic progression 
free survival (rPFS) by RECIST 1.1 
criteria with everolimus as compared to 
sunitinib as well as ORR and OS;  c-KIT 
high level expression will be associated 
with chromophobe histology and a 
greater rPFS, ORR, and OS benefit with 
everolimus as compared to sunitinib; 
and finally that HIF-1 and c-MET 
will be associated with papillary RCC 
histology and will be associated with a 
greater rPFS, ORR, and OS benefit with 
sunitinib as compared to everolimus. 
We also suspected that high levels 
of pS6 and pAKT and cMET will be 
associated with poor outcomes overall 
including shorter rPFS, OS, and low 
ORR regardless of therapy.  
We employed immunohistochemical 
studies of primary nephrectomy 
or metastatic biopsy specimens to 
examine the prognostic and predictive 
associations with progression-free and 
overall survival in this pre-specified 
prospective secondary analysis. Such 
findings could ideally permit the 
selection of patients for an mTOR 
or VEGF/MET treatment such as 
cabozantinib more optimally than 
histology or clinical risk score alone.
  
RESULTS
From September 23, 2010 through 
October 28, 2013, we accrued 109 
subjects across three (3) countries 
and 17 participating sites. One subject 
did not receive the study drug and 
Table 1 | Baseline characteristics of patients included in the present correlative IHC study as 
compared to those patients without available biomarker data. NR indicates the estimate was not 
reached. 
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tissue available for IHC studies, and 
are excluded from this analysis (see 
CONSORT diagram, Supplementary 
Figure 1). The data lock for the final 
overall survival analysis was May 2016. 
Patients in the biomarker evaluable 
population did not differ from those 
without evaluable biomarkers with the 
exception of more women (32% vs. 7%), 
more type 2 papillary (27% vs. 17%), 
and fewer intermediate MSKCC risk 
patients (56% vs. 67%) in the biomarker 
group, respectively (Table 1).  The 
majority of evaluable patients (42/78, 
54%) had metastatic papillary RCC with 
non-type 1 histology; only 3 patients 
had type 1 papillary RCC.  The second 
most common histologic subtype was 
metastatic chromophobe RCC, which 
accounted for 17% of patients, followed 
by unclassified/poorly differentiated 
RCC, comprising 8% of patients.
withdrew and was replaced, leaving 
108 evaluable subjects who were then 
randomized to sunitinib (51 subjects) 
or everolimus (57 subjects).   Biomarker 
data was available from 78 of 108 
patients (72%), with over 90% of the 
cases derived from primary tumor 
tissue from nephrectomy or renal 
biopsy, including 36 patients treated 
with sunitinib and 38 patients treated 
with everolimus.  Thirty patients (15 in 
each treatment group) had insufficient 
A
B
Figure 1: (A) Representative images of biomarker expression by immunohistochemistry from the ASPEN study according to histologic 
subtypes of papillary, chromophobe, and unclassified RCC. Note c-kit expression predominantly in chromophobe RCC, c-met expression in 
papillary RCC.  (B) Distributions of tissue IHC biomarker expression levels according to histologic subtype categorized as papillary (red), 
chromophobe (blue), and undifferentiated (green).  (C) Distributions of tissue IHC biomarker expression levels according to MSKCC risk 
groups coded as good (green), intermediate (orange), and poor (purple).
C
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Distribution of Tissue Protein 
Biomarkers
Lower protein expression scores 
were more common across all 
patients for p-Akt, HIF-1α, and 
c-kit with 1.3%, 12.8%, and 6.4% 
harboring at least 2+ expression 
by IHC.  The distribution of IHC 
scores was fairly balanced for p-S6 
and c-MET, with 44.8% and 43.6% 
of patients harboring at least 2+ 
expression by IHC (Supplementary 
Table 3). Representative IHC 
images of each biomarker across 
the 3 histologic subtypes are shown 
in Figure 1A.
Association of Tissue Protein 
Biomarkers with Histology 
and MSKCC Risk Group
Chromophobe patients had a 
greater percentage of 0 IHC values 
for p-Akt, p-S6, and c-MET, and 
as expected were more likely to 
have detectable (1+ or higher) c-kit 
expression than non-chromophobe 
RCC patients (62% vs. 5%) (Figure 
1B, Supplementary Table 3). The 
distributions were fairly uniform 
within each group for p-S6 
and c-MET.  In papillary RCC, 
c-MET expression was absent in 
9.3% of patients as compared to 
23% of chromophobe and 0% of 
unclassified tumors. However, 
any expression and intense 3+ 
expression of c-MET was detected 
in 82%, 69%, and 86% in papillary, 
chromophobe, and unclassified 
tumors, respectively, while 
intense 3+ c-MET expression was 
detectable in 14%, 0%, and 18%, 
respectively, indicating the c-MET 
expression was not restricted to 
papillary subtypes. 
Phospho-Akt,  HIF-1α, and 
c-MET scoring distributions were 
similar across the three MSKCC 
risk groups.  Patients with good 
MSKCC risk were more likely 
to have absent p-S6 (26%) as 
compared to patients with poor 
MSKCC risk (0%), and less likely 
to have intense p-S6 staining of at 
least 3+ (13% vs 55%). Patients with 
good MSKCC risk had lower scores 
A
B
Figure 2: (A) Kaplan-Meier Overall Survival Curves by Tissue Biomakers (pAkt, pS6, HIF-1α, c-kit, and 
c-MET). (B).  Kaplan-Meier Progression-Free Survival Curves by Tissue Biomakers (pAkt, pS6, HIF-1α, 
c-kit, and c-MET).
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of p-S6 while relatively more poor risk 
patients had higher IHC scores for this 
biomarker (Figure 1, Supplementary 
Table 3).  Thus, neither c-MET nor 
p-AKT staining distinguished risk 
groups, while downstream p-S6 was 
clearly associated with poor risk 
disease.
Associations  of  Tissue Biomarkers 
with Clinical Outcomes
There were 67 PFS events and 44 deaths 
in 78 patients with evaluable  tissue 
biomarker data and as of the final data 
lock in May 2016, the median follow-up 
time in 34 alive patients was 29 months 
(range=2.6-55.7).   Patients with 1+ pAkt 
tumor tissue staining had a shorter 
median OS (14.7 months) as compared 
with patients with absent p-Akt (37.9 
months). However, none of the five 
tissue biomarkers were prognostic of 
OS in univariate analysis (Figure 2A 
and Table 2).
In multivariable analysis of OS, 
however, both p-Akt and c-kit were 
statistically significant prognostic 
biomarkers of OS after multiplicity 
adjustment and adjustment for 
histologic type and MSKCC risk. The 
multivariable hazard ratio (HR) for 
death for p-Akt was 2.2 (95% CI=1.1-
4.2, FDR=0.056). On the other hand, 
detection of c-kit was associated with 
improved survival (HR=0.1;95% 
CI=0.0-0.7; FDR=0.056) irrespective of 
histology. 
None of the tissue biomarkers were 
associated with PFS overall (Table 
2B, Figure 2B). Additionally, when 
exploring a higher threshold cut-off 
for IHC positivity of 2-3+ expression, 
none of the biomarkers had statistically 
significant associations with OS or 
PFS in secondary analyses comparing 
biomarker expression 0-1 versus >2+ 
(Supplementary Tables 5A and 5B). 
Predictive Associations with 
Clinical Outcomes
Finally, we examined each of the 5 
pathway-based protein biomarkers 
for associations with outcomes of 
either sunitinib or everolimus and the 
predictive value of biomarker expression 
for superiority of one therapy over the 
other.  None of the tissue biomarkers 
were predictive of treatment benefit for 
OS or PFS for sunitinib or everolimus 
(Tables 3A and 3B) regardless of the 
IHC scoring thresholds 
(Supplementary Tables 5A 
and 5B).  Lastly, while none 
of the biomarkers were 
predictive of differential 
objective response (Tables 
4B and Supplementary 7B), 
we did note that patients 
with c-MET expressing 
tumors had a lower objective 
response rate by RECIST 
1.1 (11% ORR) as compared 
to patients with tumors 
lacking c-MET expression 
(43% ORR). In sunitinib 
treated patients, the ORR 
was 17% vs 50% in patients 
with c-MET expressing vs. 
non-expressing tumors, 
while in everolimus treated 
patients, the ORR was 6% 
vs. 33% respectively.  The 
ORR for patients with high 
c-kit expression was 0% for 
sunitinib vs. 24% for patients 
with absent c-kit expression, 
as compared to the opposite 
result for everolimus, which 
had an ORR of 25% for patients with 
high c-kit expression as compared to 6% 
for patients that lacked c-kit expression. 
DISCUSSION
The treatment of patients with metastatic 
non-clear cell RCC continues to evolve 
and improve.  Based on the ASPEN and 
ESPN randomized trials, sunitinib was 
demonstrated to have more prolonged 
progression free and overall survival 
and higher objective response rates as 
compared to everolimus3,4 overall and 
particularly in favorable/intermediate 
risk and papillary/unclassified subtypes. 
However, everolimus had clear 
activity and and improved outcomes 
in patients with poor risk disease and 
chromophobe RCC variants, mirroring 
prior prospective data derived from 
the global phase 3 temsirolimus trial. 
Recently cabozanitinb was shown to 
have superior responses and PFS as 
compared to sunitinib in advanced 
papillary RCC (both type 1 and 2), 
suggesting that dual inhibition of 
c-MET and VEGF may provide more 
durable clinical benefits11.  Here we 
sought to identify subgroups of patients 
B
Table 2: (A)  Median overall survival (OS) by tissue biomarkers for all evaluable patients. Univariate and 
multivariable hazard ratios of OS for each biomarker. Cut-point of 1+ scoring. NR indicates the estimate was 
not reached. *Adjusting for treatment arm and stratification variables (histology and MSKCC risk groups)  (B) Median 
progression-free survival (PFS) by tissue biomarkers for all evaluable patients. Univariate and multivariable 
hazard ratios of PFS for each biomarker. Cut-point of 1+ scoring. NR indicates the estimate was not reached.
A
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that may differentially respond 
to molecularly targeted therapies 
through the use of protein-
based assays of potential driver 
pathways.  While we found that 
activation of the mTOR pathway 
including low level Akt and S6 
phosphorylation was associated 
with poor risk disease and worse 
survival, these biomarkers were 
not sufficiently predictive of 
clinical benefit for everolimus 
compared to sunitinib.  While 
chromophobe patients with high 
c-kit expression had a numerically 
higher ORR with everolimus than 
sunitinib, this did not translate 
into longer PFS or OS potentially 
due to the relatively small sample 
size of this subgroup. 
Recently, we identified specific 
subsets of non-clear cell RCC 
patients that have poor outcomes 
in the ASPEN trial based on levels 
of plasma angiokines associated 
with angiogenesis, metastasis, 
and immune evasion, particularly 
osteopontin (OPN), TIMP-1, 
thrombospondin-2, hepatocyte 
growth factor (HGF), and VCAM-
116. These data suggest potential 
therapeutic targets associated 
with disease burden and 
treatment resistance.  We could 
not directly assess most of these 
biologic features in tumor tissues, 
and thus cannot correlate tumor 
angiokine expression with plasma 
levels and clinical outcomes.
However, when we could there 
was not a clear correlation with 
outcomes. For instance, we 
evaluated c-met, the receptor 
for hepatocyte growth factor, in 
tumors and found no correlation 
with c-met levels and clinical 
outcomes in non-clear cell as well 
as the subset of papillary RCC 
patients treated with sunitinib or 
everolimus, despite a prognostic 
association of high plasma 
HGF levels with poor overall 
survival5. Other assessments of 
pathway addiction such as c-met 
phosphorylation or amplification 
or splice variants, or mTOR 
pathway mutations17, 18, should be 
further evaluated against specific 
targeted therapy outcomes in this 
A
Figure 3: (A) Kaplan-Meier Overall Survival Curves by Treatment Assignment and Tissue Biomakers 
(pAkt, pS6, HIF-1α, c-kit, and c-MET).  (B)  Kaplan-Meier Progression-Free Survival Curves by Treatment 
Assignment and Tissue Biomakers (pAkt, pS6, HIF-1α, c-kit, and c-MET).
B
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context.  
Our analysis has several limitations. 
The first is the heterogeneous nature of 
our patient population, comprised of 
multiple tumor types with likely widely 
differing genotypes and biomarker 
expression profiles and differing clinical 
risk groups.  This limits our power to 
determine predictive interactions for 
individual subgroups and therapies. 
The second is the current lack of 
genotyping data in this trial at the 
present time, which does not permit 
a more detailed molecular analysis of 
pathway mutations, amplifications, 
splice variants, or expression.  We 
chose to focus our biomarker studies 
for the present analysis on protein and 
phosphoproteomic alterations given 
that the functional consequences of the 
known genomic alterations is frequently 
unknown, and we hypothesized that 
these pathway-based protein assays 
would be more functionally relevant 
to drug activity for therapies targeting 
the mTOR or VEGF pathways.  Third is 
the lack of present information in this 
trial on the activity of other pathways, 
such as the NRF2/KEAP1, fumarate 
hydratase and other metabolic 
regulators, or epigenetic regulators. 
Further investigation into these and 
other key biologic processes including 
the immune landscape of these tumors 
may shed light into future therapeutic 
directions, including combination 
VEGF/c-MET and immune checkpoint 
blockade or novel approaches. 
Our work has several strengths, 
including being the largest, prospective 
global trial conducted to date in 
this metastatic non-clear cell RCC 
population. We mandated tissue 
collection as part of eligibility, which 
ensured a robust program for biomarker 
study, and we utilized previously 
validated IHC assays with appropriate 
validated controls.  Our pathologists 
were blinded to outcome, while our 
statisticians performed the clinical 
analysis while blinded to biomarker 
studies, ensuring a lack of bias in the 
data analysis plan.  While the trial was 
open label for treatment, treatment was 
randomized and not selected based on 
any patient or tumor characteristics. 
IHC studies are relatively easy to 
conduct in clinical practice relative to 
complex genotyping assays, and thus 
this work could be readily applicable if 
successful.  Finally, we conducted long 
term follow up to ensure an adequate 
number of events for the gold standard 
of overall survival as an endpoint.
In conclusion, we demonstrate 
the negative prognostic value for Akt 
pathway activation in non-clear cell 
RCC and the positive prognostic value 
for c-kit expression in a prospective 
clinical trial of sunitinib vs. 
everolimus.  Additionally, we 
show that c-MET expression is 
associated with a poor response 
to sunitinib or everolimus, 
while c-kit expression is 
associated with a better 
response to everolimus. 
However, we were unable to 
show a predictive treatment-
biomarker interaction using the 
5 pathway-directed biomarkers 
in this study, and thus, overall 
sunitinib remained the superior 
therapy in the ASPEN trial.  
MATERIALS & METHODS
Study design and patients
This was a prospective, open-
label randomized United States 
Food and Drug Administration 
IND-exempt trial conducted 
across 17 participating global 
sites, including the United States, 
Canada, and the United Kingdom. 
Regulatory oversight in Canada and the 
UK was obtained for this trial.  After 
meeting eligibility, randomized subjects 
were assigned 1:1 to either sunitinib 
malate or everolimus at approved doses 
until disease progression.
Patients were eligible if they had 
histologically confirmed advanced RCC 
with non-clear cell pathology after local 
site review by pathology, including 
unclassified subtypes.  Mixtures of 
these non-clear cell variants were 
allowed provided they consisted 
predominantly (> 50%) of papillary, 
chromophobe or undifferentiated 
histology.  Patients with minor clear 
cell components (<50%) were permitted 
provided the dominant histology and 
presumed primary histology was non-
clear cell.  Exclusion criteria for the 
study included active untreated CNS 
metastases, prior systemic therapy for 
RCC, and collecting duct or medullary 
histology. Full eligibility details are 
provided in the primary clinical 
manuscript3.  
This study was registered as an 
International Standard Randomised 
Controlled Trial with ClinicalTrials.gov 
number NCT01108445.  All patients 
provided informed consent under an 
Table 3: (A)  Median overall survival (OS) by treatment group and tissue IHC biomarkers using a cut-point 
of 1+, including biomarker-treatment interaction p-values. NR indicates the estimate was not reached.  (B) 
Median progression-free survival (PFS) by treatment group and tissue IHC biomarkers using a cut-point of 
1+, including biomarker-treatment interaction p-values. NR indicates the estimate was not reached.
A
B
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Table 4: (A)  Objective response rate showing N (%) and odds ratio (95% CI) by IHC 0 vs. 1+ 
biomarker status.  (B) Objective response rate by treatment assignment and IHC 0 vs. 1+ biomarker 
status. 
A
institutional IRB-approved consent 
form.  This was an investigator-
initiated study, with the Duke Cancer 
Institute as lead coordinating center 
and biorepository. A contract research 
organization, inVentiv Health Clinical, 
oversaw the collection of data and 
safety monitoring on behalf of Duke 
globally.
Tissue Biomarker Studies
Primary nephrectomy or metastatic 
biopsy specimens were prospectively 
collected on all patients as part of the 
eligibility criteria for the ASPEN trial. 
Formalin-fixed paraffin embedded 
tissue was collected and underwent IHC 
studies for 5 biomarkers:  phospho-S6 
and phospho-Akt as measures of 
mTOR pathway activation; c-kit as a 
defining biomarker of chromophobe 
RCC which has been associated with 
mTOR pathway activation through 
folliculin mutations 14; c-MET total 
expression; and HIF-1α as a measure of 
VEGF pathway activation. The specific 
antibodies utilized and validated on 
control tissues, their concentration/
dilution, and methods used are 
described in Supplementary Table 1. 
Investigators and statisticians were 
blinded to the results of these biomarker 
studies at the time of outcome analysis.
Outcomes
The primary endpoint of this tissue 
biomarker study was overall survival 
(OS), defined as the interval from 
date of random assignment until date 
of death or date of last follow-up.  A 
key secondary outcome included 
radiographic progression-free survival 
(PFS), defined as the time from date of 
random assignment until date of disease 
progression (by RECIST 1.1 criteria), 
a new primary malignancy, or death, 
whichever occurred first.  Other pre-
specified efficacy secondary endpoints 
included radiographic response 
rates per RECIST 1.1, and clinical 
benefit response (CBR), defined as the 
composite sum of partial response, 
complete response, and prolonged 
stable disease for more than 6 months. 
Objective response rate (ORR) was 
defined as the sum of complete and 
partial response by RECIST 1.1.
Statistical analysis
The five tissue biomarkers (phospho-S6, 
phospho-Akt, c-kit, HIF-1α, and 
c-MET) include the IHC scores of 0, 
1+, 2+, or 3+.  Missing data from the 78 
evaluable patients were excluded from 
the analyses and resulted from either 
an insufficient amount of tumor to 
categorize the sample, the sample being 
of an unacceptable quality, or a lack of 
tissue provided by the patient.  All five 
tissue biomarkers were dichotomized 
and analyzed using two pre-specified 
cut-points in the statistical analysis 
plan. The primary analysis was based 
on 0 vs. 1+ whereas the secondary 
analysis was 0-1 vs. 2+, where the “1+” 
group included scores of 1+, 2+, and 3+, 
and the “2+” group included scores of 
2+ and 3+.  The proportional hazards 
model was utilized to determine the 
prognostic importance of the tissue 
biomarkers in predicting OS and PFS 
adjusting for the treatment arm and 
the stratification factors (histologic 
type and MSKCC risk groups).  The 
association of each biomarker with OS 
and PFS was summarized with a hazard 
ratio (HR) and 95% confidence interval 
(CI) for this exploratory analysis, while 
p-values were adjusted for multiplicity 
using the false discovery rate (FDR) of 
0.056, and we considered FDR<0.1 to be 
statistically significant.  Additionally, 
the proportional hazards model was 
used to test for each of the tissue 
biomarker-treatment interaction terms 
in predicting OS and PFS.  The Kaplan-
Meier approach was used to estimate 
the OS and PFS distributions. 
When assessing the association of 
the biomarkers with histologic subtype, 
we classified all papillary tumors, 
including types I and II, as “papillary.” 
Chromophobe tumors were designated 
“chromophobe,” and the remaining 30 
patients fell into the “undifferentiated” 
category.  Patients with an MSKCC risk 
score of 0 were classified as having 
“good” risk, while patients who had 
MSKCC risk scores of either 1 or 2 were 
assigned to the “intermediate” group, 
and those with a score of 3 or above 
were categorized as “poor.”  
Furthermore, logistic regression 
analysis was used to test for the 
prognostic importance of the tissue 
biomarkers in predicting objective 
response rate. Odds ratios (OR) 
and 95% confidence intervals (CI) 
summarized these findings.  The final 
statistical analysis plan was approved 
by the Duke IRB on August 14, 2014. 
All analyses were performed using R 
version 3.5.3 and were adjusted for 
multiplicity using the false discovery 
rate (FDR) in determining whether any 
of tissue biomarkers were prognostic or 
predictive of OS or PFS.
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Complete resection of renal tumor by radical 
or partial nephrectomy:
•  Predominately clear cell non-metastatic* RCC
• Pathological stage:
– pT2a, G3 or G4, N0, M0
– pT2b, G any, N0, M0
– pT3(a, b, c), G any, N0, M0
– pT4, G any, N0, M0
– pT any, G any, N1, M0
• ECOG 0-1
• No prior anti-cancer Tx, for RCC








• Follow-up Visits 1 & 2
•  Survival follow-up




















is exploring adjuvant IO
regimen for RCC patients
To find out if your patients are eligible for this 
trial, learn more at BMSStudyConnect.com/KCJ.
Reference: Data on file. Clinical protocol CA209-914. Princeton, NJ: Bristol-Myers Squibb Company, 2020.
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Bristol Myers Squibb is currently conducting a clinical trial exploring immuno-oncology (IO) agents for early-stage, high-risk 
renal cell carcinoma (RCC): CheckMate 914.
CheckMate 914 is a randomized, Phase 3 clinical trial evaluating adjuvant nivolumab alone or in combination with ipilimumab 
in patients who underwent radical or partial nephrectomy and who are at high risk of relapse.
Timing is critical
Research post-surgery plans before surgery happens. For this clinical trial, randomization must occur between 
4 and 12 weeks from the date of nephrectomy
Exploring beyond observation
This study seeks to investigate the role of an IO agent compared to the current standard of care (observation)
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